Key Highlights

  • Adjusted EPS of $1.96 beat consensus estimates, rising 16% year over year
  • Net revenues reached $10.15 billion, up 9.1% on a reported basis
  • International smoke-free gross profit grew nearly 20% organically
  • Zyn US shipments declined due to inventory dynamics, not demand erosion
  • Full-year adjusted EPS guidance maintained at $8.36 to $8.51

A Strong Quarter Defined by Structural Momentum

Philip Morris International (NYSE:PM) delivered a convincing first-quarter performance for 2026, with its accelerating transition toward smoke-free products driving results that exceeded analyst expectations across core profitability metrics. Shares closed up approximately 7% on April 22, reflecting investor confidence in the structural trajectory of the business rather than any single quarter's headline numbers.

Adjusted diluted earnings per share reached $1.96, surpassing consensus forecasts of approximately $1.83 to $1.89. Net revenues of $10.15 billion rose 9.1% on a reported basis and 2.7% organically, ahead of management's own forecast for broadly flat organic growth. Adjusted operating income grew 10%, while adjusted gross profit expanded to $6.9 billion, reflecting 3.8% organic growth and 70 basis points of margin improvement.

The quarter was not without friction. The US segment faced a difficult comparison period, and Zyn nicotine pouch shipments declined meaningfully. Yet the market's reaction suggested investors focused on what the results reveal about the company's longer-term earnings model rather than its near-term US complications.

IQOS Remains the Engine of International Profitability

The international smoke-free segment delivered a striking performance. In-market sales for IQOS grew nearly 11% in adjusted terms, with strong momentum across Europe, Japan, South Korea, and the newly launched Taiwan market, where IQOS captured approximately 6% national market share within one quarter of launch, reaching close to 8% share in Taipei by March.

International smoke-free gross profit expanded close to 30% in dollar terms, with segment gross margins exceeding 70%, an increase of 210 basis points year over year. This reflects the compounding effect of pricing actions, manufacturing productivity gains, and growing scale benefits on IQOS consumables.

The multi-category strategy continued to gain traction. VEEV reached joint number one position in Europe across 19 markets per Nielsen data, with quarterly shipments surpassing 1 billion equivalent units for the first time. International Zyn volumes, excluding the more mature Nordic markets, grew approximately 42% on a comparable basis. Meanwhile, the combustible segment demonstrated pricing discipline, with organic gross profit expanding 3.9% despite cigarette volume declines at the higher end of expectations.

US Business Faces Comparison Headwinds, Not Category Deterioration

Zyn shipments fell to 155 million cans in the quarter, declining sharply against a prior year period that included approximately 40 million cans of inventory rebuilding. Stripping out that base effect, the underlying shipment volume was closer to 175 million cans, broadly consistent with the 10% consumer offtake growth reported through Nielsen data.

Management separated inventory mechanics from consumer demand clearly. The company does not yet compete in the fastest-growing flavor and higher-nicotine strength segments of the US nicotine pouch market, a gap it expects to address through pending regulatory approvals, including the Zyn Ultra application currently under active scientific review by the FDA. Higher promotional investment and a normalising comparison base are expected to support progressively improved US performance through the second half of 2026.

Guidance Reaffirmed With Updated Currency Assumptions

Management reaffirmed full-year 2026 guidance for organic net revenue growth of 5% to 7% and organic operating income growth of 7% to 9%. Incorporating a currency tailwind now estimated at $0.25 at prevailing rates, full-year adjusted EPS guidance stands at $8.36 to $8.51, representing reported growth of approximately 11% to 13%.

For the second quarter, management guided for adjusted EPS of $2.02 to $2.07, alongside mid-single-digit organic net revenue growth. Japan's April excise-driven price increase will create near-term HTU in-market sales volatility as pantry loading effects reverse. Macro uncertainty, particularly related to the Middle East conflict, was cited in higher transport and input cost assumptions, though no material deterioration in consumer demand has been observed.

Conclusion

Philip Morris International's first quarter illustrates a business in structural transition that is beginning to harvest the financial returns of that shift. Pricing power, smoke-free mix, and currency tailwinds converged to deliver results well ahead of expectations, even as US headwinds and volume pressures persisted. With IQOS momentum broadening across geographies, innovation pipelines advancing, and full-year guidance intact, the near-term narrative is one of compounding earnings power. The more consequential question for investors is whether regulatory progress on Zyn Ultra and IQOS ILUMA in the US can extend that momentum into its largest remaining growth market.